Pegaspargase

Pegaspargase
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a695031
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    Chemical and physical data
    Formula C1377H2208N382O442S17
    Molar mass 31731.9 g/mol
     ☒N☑Y (what is this?)  (verify)

    Pegaspargase /pəˈɡæspərɡeɪz/, trade name Oncaspar, is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation. The drug is manufactured by Exelead, Inc.

    It is used in the treatment of acute lymphoblastic leukemia.[2][3]

    See also

    PEGylation

    References

    1. ↑ "UNM Cancer Center". Archived from the original on September 3, 2006. Retrieved 2007-08-28.
    2. ↑ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
    3. ↑ Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics. 5 (6): 492–496.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.